The Brown Group focuses on reducing disability in multiple sclerosis, one of the most common causes of disability in the young. We use real-world data to optimise the use of existing disease-modifying therapies and to explore novel repair strategies (e.g. Brown et al JAMA 2019; Kalincik, Brown et al Lancet Neurol 2017). We run remyelination trials in people with MS, focusing on novel imaging outcomes to detect treatment effects and illuminate disease biology (e.g. Brown et al Lancet Neurol 2021). And we use IT to improve and personalise the care of people with MS and enrich MS registries.
